It is known that trastuzumab, combined with a neoadjuvant chemotherapy regimen including anthracycline and a taxane, achieves a pathological complete response (pCR) of 38%, compared to 19% obtained with chemotherapy only (p = 0.001) in patients with HER2-positive breast cancer (BC) [2]. This evidence concerns the gene ERBB2 and breast carcinoma.